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Abstract
Most antithrombotic approaches target prevention rather than the more clinically relevant issue of resolution of an existing
thrombus. In this study, we describe a novel and effective therapeutic strategy for ex vivo clearance of pre-existing platelet
thrombus by the combination of two bifunctional platelet GPIIIa49-66 ligands that target different parts of the arterial
thrombus. We produced an additional GPIIIa49-66 agent (named APAC), which homes to activated platelets. Like our
previously described SLK (which targets newly deposited fibrin strands surrounding the platelet thrombus), APAC destroys
platelet aggregates ex vivo in an identical fashion with 85% destruction of platelet aggregates at 2 hours. The combined
application of APAC and SLK demonstrated a ,2 fold greater platelet thrombus dissolution than either agent alone at a low
concentration (0.025 mM). Platelet-rich clot lysis experiments demonstrated the time required for 50% platelet-rich fibrin clot
lysis (T50%) by APAC (9566.1 min) or SLK (14567.1 min) was much longer than that by combined APAC+SLK (6567.6 min)
at the final concentration of 0.025 mM (APAC+SLK vs APAC, p,0.05; APAC+SLK vs SLK, p,0.01). Thus these low
concentrations of a combination of both agents are likely to be more effective and less toxic when used therapeutically in
vivo.
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Introduction
Stroke is the second leading cause of death worldwide [1,2].
Approximately 80% of strokes are caused by focal cerebral
ischemia due to arterial occlusion, whereas up to 20% are caused
by intracerebral hemorrhages [3,4]. In ischemic stroke, treat-
ment options are limited. Therapeutic thrombolysis is restricted
to the first few hours after onset [5–7], and the utility of current
platelet aggregation inhibitors [8,9], including aIIbb3 antagonists,
is counterbalanced by the risk of intracerebral bleeding
complications. Thus, there is a pressing need to develop better
and safer therapeutic approaches with an improved benefit-to-
risk ratio.
We have previously described a unique antiplatelet autoanti-
body in patients with HIV- or hepatitis C-related thrombocyto-
penia that recognizes platelet integrin GPIIIa49-66 epitope and
induces complement-independent platelet fragmentation and
death by generation of reactive oxygen species through the
activation of 12-lipoxygenase and NADPH oxidase [10–14].
Subsequently, we identified a human single-chain fragment
variable region (scFv) antibody (named A11), which induces
comparable oxidative platelet fragmentation as the patient
antibody [15]. To enhance its targeting, we produced a
bifunctional A11-plasminogen first kringle-l agent (named SLK),
which homes to newly deposited fibrin strands within and
surrounding the platelet thrombus, reducing effects on non-
activated circulating platelets [16]. This approach was successful
for the clearance of preexisting arterial thrombus in murine
models of ischemic stroke. Furthermore, we showed SLK to be
associated with an even more modest drop in platelet count
compared to A11 (11% versus 18%) [16]. In the current study we
tested the hypothesis that synergistic administration of SLK with
another GPIIIa49-66 targeting agent (A11) that homes to
activated platelets will provide a better and safer therapeutic
strategy for cerebral ischemia. We have developed an additional
bifunctional platelet integrin GPIIIa49-66 agent (named APAC),
and investigated its synergy with SLK for the dissolution of ex vivo
platelet thrombus at low concentrations.
Materials and Methods
Materials
All reagents were obtained from Sigma (St. Louis, MO), unless
otherwise designated. E.coli strains Rosseta, plasmid pET-29a and
Ni-NTA agrose resin were from Novagen (Nottingham, UK).
Restriction enzymes were obtained from New England Biolabs
(Beverly, MA). Tomlinson human scFv monoclonal phage J library
was kindly provided by MRC Geneservice (Cambridge, UK).
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A11-PAC-1 (APAC) reagent
The Tomlinson J phage Library was used to screen against a
biotin conjugated GPIIIa49-66 peptide. Specific clones enriched
for anti-GPIIIa49-66 Ab’s were screened and one clone named
A11 was selected for highest binding avidity, as described [15].
PAC-1 is an IgM-k murine monoclonal antibody that, like
fibrinogen, binds to aIIbb3 only on activated platelets. The binding
of PAC-1 to activated platelets mainly depend on the RYD
sequence within the H-CDR3 (heavy chain variable region) which
mimics the RGD sequence in fibrinogen [17]. We commercially
produced the cDNA from the heavy and light chain variable
region. We have substituted the published RYD binding region
with RGD for possible greater integrin binding. We next linked
A11 to the heavy-light chain variable binding region of PAC-1
(APAC) with a (GSTSG)3SGSGI linker. The forward primer of
PAC-1 (PACF) 59- ACAAGTGGTGGATCTACTAGTGGC-
TCTGGATCCGGAATTCAGGTGCAGCTGAAGCAGTCA-39
have three portions: the first 20 bp is the reverse complement
sequence ofpartoftheSCFCprimer.Theresidualsequenceencodes
for the C-terminal half of the linker and the beginning of the PAC-1
domain. The backward primer (PACR) is 59-TAGGATCCGC-
GGCCGCTTTTATTTCCAGCTT GGTCCC-39. The 1548 bp
ScFv-A11-Linker-PAC (APAC) was inserted into pET-29a to
generate pET29a- APAC. E.coli Rosetta cells transformed with the
expression vectorpET29a-APACwerecultured in1 L2YT medium
containing carbenicillin (50 mg/ml) and chloramphenicol (34 mg/ml)
w i t hs h a k i n ga t3 7 uCuntilthe OD (600 nm)was 0.4–0.6.Production
was induced by the addition of 1 mM IPTG and the cells incubated
at 37uC for 4 hours with shaking. Cells were then harvested and the
pellets frozen at 220uC for storage. Refolding and purification steps
were performed at 4uC as previously described [16].
Platelet activation
Platelets from platelet-rich plasma (PRP) were activated by
addition of 20 mM ADP (Helena Lab, Beaumont, TX), and then
incubated for 20 minutes at room temperature with 1 mM APAC.
Secondary staining was performed with monoclonal, FITC-
labeled anti-His (6)-tag antibody (Dianova, Hamburg, Germany).
The binding to the platelets was determined by flow cytometry
using a FACScan (BD Biosciences, Mountain View, CA).
Platelet particle assay
Gel-filtered human platelets or thrombin PAR-1 agonist
TFLLRN-activated human platelets (100 mM TFLLRN) were
stained with anti-CD61-FITC respectively, and then treated with
various concentrations of APAC for 4 hours at 37uC. Fluorescent-
labeled platelets/particles were measured by flow cytometry using
a FACScan (BD Biosciences, Mountain View, CA) as previously
described [13].
Disaggregation and destruction of ex vivo human
platelet aggregates
For collagen-induced aggregates, 1 mg/mL collagen (Helena
Lab, Lubbock, TX) was incubated with human platelets for 1 hour
at 37uC with intermittent shaking, followed by gravity sedimen-
tation at room temperature for 0.5 h. The top 50% volume was
removed and the remainder of the platelet aggregate suspension
was added directly into Tyrode buffer, pH 7.4 with testing
reagents. A11, SLK, APAC or SLK+APAC were added for
various time intervals, and the remaining platelet/aggregate was
enumerated as previously described [16].
Platelet-rich fibrin clot lysis assay
Platelet-rich fibrin clots were formed as described [18]. Briefly,
clotting was initiated by adding human thrombin (0.6 NIH unit/
mL), CaCl2 (to 20 mM) and human fibrinogen (1 mg/mL) in
human platelet. Each clot in the microtiter plate was incubated
with PBS containing plasmin (1 pmol/well) and varied concen-
trations of control scFv Ab (13CG2), SLK, APAC, SLK+APAC.
After 30 min the surface of each clot was washed gently with
PBST (PBS with 0.1% Tween-20) to remove unbound plasmin
and agents. The platelet-rich clot lysis process was monitored by
measuring turbidity changes in the absorbance at 405 nm at
25uC using a microtiter plate reader operated in the kinetic
mode. All readings reached the low plateau were taken as
completion of clot lysis. Duplicate wells were prepared for each
concentration of test agents in each experiment, and the
experiment was repeated three times. T50% represented the time
to achieve a 50% lysis of the platelet-rich clot. It was calculated
from the OD/time data.
Statistics
Data are expressed as mean 6standard deviation (SD). One
way analysis of variance (ANOVA) followed by Tukey’s test for
multiple comparisons. In the case of single comparisons, student’s
t-test was applied. P-values#0.05 were considered statistically
significant.
Results
Production and characterization of a bifunctional APAC
capable of homing to active platelets
To enhance the protective effect of A11, we devised an
approach to home A11 to activated platelets by coupled A11 with
scFv-PAC-1 (named APAC) as previously reported for SLK [16].
Figure 1 demonstrates the rationale of the approach.
The specificity of APAC binding to activated platelets was
determined by flow cytometry. Figure 2A demonstrates APAC
preferably bound to ADP-activated human platelets, whereas it
did not bind to human resting platelets or mouse platelets.
Figure 2B demonstrates APAC binding to ADP-activated human
platelets in a concentration-dependent manner, which is ,4.8 fold
more potent than parent A11 or SLK (which targets newly
deposited fibrin strands surrounding the platelet thrombus).
We next investigated the effect of APAC on platelet fragmen-
tation. As demonstrated by Figure 2C, APAC has a preferential
effect on activated platelets pretreated with the thrombin PAR-1
agonist TFLLRN, particularly at low APAC concentrations (,4.6-
fold greater sensitivity). Notably, platelet fragmentation induced by
APAC was inhibited by the peroxide inhibitors catalase and
diphenylene iodonium (DPI), as previously reported for anti-
GPIIIa49-66 Abs, indicating the requirement of an oxidation
reaction for platelet fragmentation (data not shown).
Since APAC binds to human platelets, but not mouse platelets,
we could not test the effect of APAC in vivo in a mouse model as we
have previously reported. We therefore designed an ex vivo
experiment with human platelets. Like SLK, a total of 0.1 mM
APAC destroyed ex vivo platelet aggregates in an identical fashion
with ,85% destruction of platelet aggregates at 2 hours
(Figure 2D).
Synergy of APAC and SLK on ex vivo platelet aggregate
dissolution and platelet-rich clot lysis
Because bifunctional APAC binds to activated platelets and
SLK binds fibrin surrounding the platelet thrombus, we designed
Synergy of Antibodies against b3 Integrin
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together at a low concentration. As hypothesized, platelet
aggregate dissolution by the combination of SLK and APAC
was ,2 fold greater than either agent alone at 0.025 mM
(Figure 3A). Similar results were obtained with a combination of
SLK and APAC at the final concentrations of 0.05 or 0.1 mM
(,1.81-fold and 2.16-fold greater sensitivity, respectively; data not
shown).
Figure 1. Generation of a bifunctional APAC capable of homing to active platelets. (A) Schematic diagram describing cloning strategy for
the fusion construct. (B) Plasmid Construct. (C) 12% SDS-PAGE analysis of five aliquots of purified fusion protein (,60 KD) with Ni-column following
induction by 1 mM IPTG.
doi:10.1371/journal.pone.0027012.g001
Figure 2. Characterization of a bifunctional APAC agent capable of homing to active platelets. (A) Binding assay of APAC to platelets. (a)
resting mouse platelets; (b) ADP-stimulated mouse platelets; (c) resting human platelets; (d) ADP-stimulated human platelets, respectively. (B) Binding
assay of APAC versus A11 to activated human platelets determined by flow cytometry. Data were presented as mean 6SD (n=3). (C) Effect of APAC
on platelet fragmentation. Bars labeled 2, 3 and 4 after 1 refer to serial doubling dilutions of 1:2–1:16 respectively (0.1 mM APAC), n=4, SD is given. (D)
Dissolution of ex vivo collagen-induced platelet aggregates with APAC. Data and SD are given for 3 separate experiments at 0.1 mM reagent in which
each time point represents 5 measurements.
doi:10.1371/journal.pone.0027012.g002
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performed platelet-rich clot lysis experiments which partially
simulate the physiologic condition. Figure 3B demonstrated the
time required for 50% platelet-rich fibrin clot lysis (T50%)b y
APAC (9566.1 min) or SLK(14567.1 min) was much longer than
that by APAC+SLK (6567.6 min) at the final concentration of
0.025 mM (APAC+SLK vs APAC, p,0.05;APAC+SLK vs SLK,
p,0.01).
Discussion
Currently, the aIIbb3 integrin has been utilized as a therapeutic
target for thrombosis and occlusion due to coronary artery stenting
[19]. A single-chain variable fragment antibody that specifically
blocks the activated form of GPIIb/IIIa has been successfully
produced [20–22]. In contrast to clinically used anti-platelet agents
[23–26], none of which are conformation specific, scFvs
specifically targeting activated platelets do not induce conforma-
tional changes in GPIIb/IIIa or outside-in signaling, thereby
avoiding unwanted global activation of platelets [21]. The
exclusive binding property of these scFvs to activated platelet-
specific is mediated by RXD motifs in the heavy chain
complementary-determining region (CDR) 3 of the antibodies
[22]. While these blockers selectively recognize activated platelets,
they allow the necessary physiological functions of platelets,
including cell adhesion and spreading on immobilized fibrinogen
[22]. Therefore, activation-specific GPIIb/IIIa blockade via
human single-chain antibodies represents a promising novel
strategy for antiplatelet therapy an enhanced benefit to risk ratio.
In the present study, we report a novel and effective therapeutic
strategy for the clearance of pre-existing platelet thrombus by the
synergistic administration of a low concentration of two bifunc-
tional antibodies against b3 integrin. Compared with other anti-
aIIbb3 antibodies, APAC has a different mechanism of action and
has distinct properties that may be of clinical value. It directly
dissolves the already-formed platelet thrombus by inducing
oxidative platelet fragmentation. The selectivity of APAC for
activated platelets is high. The 4.6 fold difference between the
fragmentations of activated platelets versus resting platelets
prevents the possible fragmentation of non-activated circulating
platelets. Since APAC binds to human platelets but not mouse
platelets, we could not test the effect of APAC in vivo using mouse
models. However, current data demonstrates APAC is more
effective than SLK on ex vivo platelet aggregate dissolution
(Figure 2D) and platelet-rich clot lysis (Figure 3B). We have
previously shown that SLK was effective for clearance of pre-
existing arterial thrombus in murine models of ischemic stroke
[16]. It has no effect on platelet function and minimal effect on
platelet count (,11% decrease) [16]. We therefore infer that
APAC would probably provide better protection with a low
bleeding risk in vivo compared to SLK. Moreover, this study
clearly demonstrates that combinations of both agents at low
concentrations (0.025 mM) are more effective than either agent
alone for the dissolution of existing platelet thrombus. Thus in
potential future clinical applications, the synergistic administration
of both agents will likely be more effective and less toxic in vivo at
these low concentrations. We hope that in the future our
preclinical data will lead to Phase I testing in humans, in whom
we expect APAC to provide a superior treatment option for
ischemic stroke.
These findings provide a proof-of-principle for the development
of a novel approach to dissolve pre-existing arterial thrombosis by
the synergistic administration of low concentrations of two
bifunctional GPIIIa49-66 ligands targeting different part of the
platelet thrombus, which will contribute to preventing ischemic
events as well as likely having a high benefit-to-risk ratio.
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Figure 3. Synergy of APAC and SLK on ex vivo platelet aggregate dissolution and platelet-rich clot lysis. (A) Platelet aggregates were
prepared as described above. Black bars refer to platelet aggregate size at zero time. The 3 companion hatched bars refer to platelet aggregate size at
2 hours. Concentration of SLK and APAC was at 0.025 mM. SLK+APAC double hatched bar refers to final SLK and APAC concentration at 0.025 mM
each. (B) Platelet-rich clots were formed on the wells of ELISA plate. The clots were treated with 0.025 mM Ctl scFv (13CG2) or SLK or APAC or
SLK+APAC. SLK+APAC refer to final SLK and APAC concentration at 0.025 mM each. The relative clot turbidity was calculated by detecting the
decrease of the absorbance at OD405. The mean6SD. came from 3 separate experiments. Each time point represents 5 measurements.
doi:10.1371/journal.pone.0027012.g003
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